These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 2672016

  • 1. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
    Lamm DL, Crissmann J, Blumenstein B, Crawford ED, Montie J, Scardino P, Grossman HB, Stanisic T, Smith J, Sullivan J.
    Prog Clin Biol Res; 1989; 310():263-70. PubMed ID: 2672016
    [No Abstract] [Full Text] [Related]

  • 2. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
    Fisher HA.
    Prog Clin Biol Res; 1989; 310():275-83. PubMed ID: 2505271
    [No Abstract] [Full Text] [Related]

  • 3. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
    Witjes WP, van der Meijden PM, Roos EP, Witjes JA, Steerenberg PA, Doesburg W, Debruyne FM.
    Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
    van der Meijden PM, Debruyne FM, Steerenberg PA, de Jong WH, Doesburg W.
    Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
    [No Abstract] [Full Text] [Related]

  • 6. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study.
    Mori K, Lamm DL, Crawford ED.
    Urol Int; 1986; 41(4):254-9. PubMed ID: 3538593
    [Abstract] [Full Text] [Related]

  • 7. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E, Jauhiainen K, Alfthan O.
    Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
    [No Abstract] [Full Text] [Related]

  • 8. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM, van der Meijden AP, Schreinemachers LM, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg EJ.
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract] [Full Text] [Related]

  • 9. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 12. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM, van der Meijden AP, Franssen MP.
    Prog Clin Biol Res; 1989 Apr; 303():435-46. PubMed ID: 2506556
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Our experience in the treatment of superficial cancer of the bladder with BCG].
    Martínez E, Díaz I, Salvador J, Viladoms JM, Zungri E, Solé-Balcells FJ.
    Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
    [Abstract] [Full Text] [Related]

  • 15. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S.
    Prog Clin Biol Res; 1989 May; 310():193-205. PubMed ID: 2771993
    [No Abstract] [Full Text] [Related]

  • 16. The role of adriamycin and epirubicin in superficial bladder cancer and carcinoma in situ.
    da Silva FC.
    Prog Clin Biol Res; 1989 May; 303():401-10. PubMed ID: 2675001
    [No Abstract] [Full Text] [Related]

  • 17. BCG vaccine in urinary bladder cancer.
    Brosman SA.
    West J Med; 1991 Dec; 155(6):633. PubMed ID: 1812634
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y, Nomata K, Noguchi M, Eguchi J, Koga S, Yamashita S, Hayashi M, Kanatake H.
    Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.